MCID: SRS001
MIFTS: 53

Serous Cystadenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Serous Cystadenocarcinoma

MalaCards integrated aliases for Serous Cystadenocarcinoma:

Name: Serous Cystadenocarcinoma 12 15
Cystadenocarcinoma, Serous 44 73
Cystadenocarcinoma Serous 55
Serous Adenocarcinoma 12
Serous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3114
MeSH 44 D018284
NCIt 50 C3778 C40101
SNOMED-CT 68 90725004
UMLS 73 C0206701

Summaries for Serous Cystadenocarcinoma

Disease Ontology : 12 A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue forming serous lesions.

MalaCards based summary : Serous Cystadenocarcinoma, also known as cystadenocarcinoma, serous, is related to uterine corpus serous adenocarcinoma and ovarian serous cystadenocarcinoma. An important gene associated with Serous Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and GPCR Pathway. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, pancreas and t cells, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and Decreased HPV16-GFP infection

Wikipedia : 76 Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma... more...

Related Diseases for Serous Cystadenocarcinoma

Diseases related to Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
# Related Disease Score Top Affiliating Genes
1 uterine corpus serous adenocarcinoma 33.4 ERBB2 FBXW7 PIK3CA PPP2R1A TP53
2 ovarian serous cystadenocarcinoma 32.1 AKT1 ERBB2 ESR2 FBXW7 HRAS MUC16
3 primary peritoneal carcinoma 31.5 ERBB2 MUC16 PGR TP53 VEGFA
4 adenocarcinoma 30.8 AKT1 ERBB2 HRAS PIK3CA TP53 VEGFA
5 ovarian clear cell carcinoma 30.2 PIK3CA PPP2R1A TP53 ZNF217
6 cervical adenocarcinoma 30.1 ERBB2 PGR TP53
7 ovarian cystadenocarcinoma 30.1 HRAS UBE4A ZNF217
8 in situ carcinoma 30.0 ERBB2 PGR TP53
9 carcinosarcoma 30.0 ERBB2 HRAS PGR PIK3CA TP53
10 cystadenocarcinoma 29.9 AKT1 ERBB2 FBXW7 HRAS MUC16 PGR
11 transitional cell carcinoma 29.9 ERBB2 HRAS TP53
12 wilms tumor 1 29.8 ERBB2 FBXW7 PGR TP53
13 endometriosis 29.7 ESR2 PGR VEGFA
14 adenomyosis 29.7 MMP2 PGR VEGFA
15 fallopian tube carcinoma 29.7 ERBB2 PGR TP53 VEGFA
16 lymphangioleiomyomatosis 29.3 MMP14 MMP2 PGR
17 ovarian cancer 1 29.2 AKT1 ERBB2 MMP2 PIK3CA TP53 VEGFA
18 endometrial adenocarcinoma 29.1 AKT1 ERBB2 ESR2 PGR TP53 VEGFA
19 uterine carcinosarcoma 29.0 ERBB2 ESR2 FBXW7 HRAS PGR PIK3CA
20 endometrial cancer 28.7 AKT1 ERBB2 ESR2 HRAS MMP2 MUC16
21 lung cancer susceptibility 3 28.5 AKT1 ERBB2 ESR2 HRAS MMP2 PIK3CA
22 ovarian cancer 28.2 AKT1 ALPP ERBB2 ESR2 MMP14 MMP2
23 breast cancer 27.9 AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
24 pancreatic serous cystadenocarcinoma 12.7
25 peritoneal serous adenocarcinoma 12.2
26 fallopian tube serous adenocarcinoma 12.2
27 ovary serous adenocarcinoma 12.2
28 uterine ligament serous adenocarcinoma 12.2
29 cervical serous adenocarcinoma 12.2
30 ovarian serous carcinoma 11.5
31 papillary serous adenocarcinoma 11.3
32 adult hepatocellular carcinoma 10.3 PIK3CA TP53
33 endometrium carcinoma in situ 10.3 PGR TP53
34 malignant spiradenoma 10.3 PIK3CA TP53
35 gastric papillary adenocarcinoma 10.3 ERBB2 TP53
36 apocrine adenoma 10.2 HRAS PIK3CA
37 prostate adenoid cystic carcinoma 10.2 HRAS PIK3CA
38 scirrhous adenocarcinoma 10.2 ERBB2 PGR
39 breast apocrine carcinoma 10.2 ERBB2 PGR
40 glassy cell carcinoma of the cervix 10.2 ERBB2 PGR
41 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.2 PIK3CA PPP2R1A TP53
42 pleomorphic adenoma carcinoma 10.2 ERBB2 TP53
43 breast squamous cell carcinoma 10.2 ERBB2 PIK3CA TP53
44 intracystic papillary adenoma 10.2 ERBB2 PGR
45 skin squamous cell carcinoma 10.2 HRAS PIK3CA TP53
46 epithelial-myoepithelial carcinoma 10.2 FBXW7 HRAS TP53
47 prostate squamous cell carcinoma 10.2 HRAS PPP2R1A TP53
48 spitz nevus 10.2 HRAS TP53
49 breast metaplastic carcinoma 10.2 ERBB2 PGR
50 breast malignant phyllodes tumor 10.2 PGR TP53

Graphical network of the top 20 diseases related to Serous Cystadenocarcinoma:



Diseases related to Serous Cystadenocarcinoma

Symptoms & Phenotypes for Serous Cystadenocarcinoma

GenomeRNAi Phenotypes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 ALPP ERBB2 HRAS PPP2R1A VEGFA
2 Decreased HPV16-GFP infection GR00350-A 9.26 FBXW7 HRAS PIK3CA UBE4A
3 Increased cell death HMECs cells GR00103-A-0 9.1 FBXW7 PGR PIK3CA PPP2R1A TP53 ZNF217

MGI Mouse Phenotypes related to Serous Cystadenocarcinoma:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.36 AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
2 behavior/neurological MP:0005386 10.33 AKT1 ERBB2 ESR2 HRAS MMP14 PGR
3 homeostasis/metabolism MP:0005376 10.32 AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
4 endocrine/exocrine gland MP:0005379 10.28 AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
5 cellular MP:0005384 10.27 AKT1 ERBB2 ESR2 FBXW7 MMP14 PGR
6 growth/size/body region MP:0005378 10.26 AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
7 mortality/aging MP:0010768 10.23 AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
8 integument MP:0010771 10.19 AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
9 embryo MP:0005380 10.15 AKT1 ERBB2 FBXW7 MMP14 PGR PIK3CA
10 neoplasm MP:0002006 10.14 AKT1 ERBB2 ESR2 FBXW7 HRAS MMP2
11 craniofacial MP:0005382 10.11 ERBB2 FBXW7 HRAS MMP14 MMP2 TP53
12 digestive/alimentary MP:0005381 10.1 ERBB2 ESR2 FBXW7 HRAS MMP14 TP53
13 muscle MP:0005369 10.09 AKT1 ERBB2 ESR2 MMP14 MMP2 PGR
14 nervous system MP:0003631 10.07 AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
15 normal MP:0002873 10 AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
16 limbs/digits/tail MP:0005371 9.95 ERBB2 ESR2 MMP14 PGR TP53 VEGFA
17 no phenotypic analysis MP:0003012 9.92 ESR2 HRAS MMP14 PGR PIK3CA TP53
18 reproductive system MP:0005389 9.81 AKT1 ERBB2 ESR2 MMP14 PGR PIK3CA
19 respiratory system MP:0005388 9.61 AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
20 skeleton MP:0005390 9.32 AKT1 ERBB2 ESR2 HRAS MMP14 MMP2

Drugs & Therapeutics for Serous Cystadenocarcinoma

Drugs for Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
5
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
6
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
7
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
8
Epirubicin Approved Phase 3 56420-45-2 41867
9
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 123948-87-8, 119413-54-6 60700
10
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
11
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
12
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
13
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
14
Olaparib Approved Phase 2, Phase 3,Phase 1,Early Phase 1 763113-22-0 23725625
15
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
16
Letrozole Approved, Investigational Phase 2, Phase 3,Phase 3,Early Phase 1 112809-51-5 3902
17
Gemcitabine Approved Phase 3,Phase 1,Phase 2 95058-81-4 60750
18
Metformin Approved Phase 2, Phase 3,Phase 1,Early Phase 1 657-24-9 14219 4091
19
Trametinib Approved Phase 2, Phase 3,Phase 1 871700-17-3 11707110
20
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
21
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
22
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
23
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Not Applicable 59-30-3 6037
25
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
26
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
27
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
28 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
29 Antimitotic Agents Phase 3,Phase 2,Phase 1
30 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
31 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
32 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
33 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
34 Hormones Phase 2, Phase 3,Phase 3,Early Phase 1,Not Applicable
35 Immunoglobulin G Phase 3,Phase 2,Phase 1
36 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
37 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
38 Antibodies Phase 3,Phase 2,Phase 1
39 Immunoglobulins Phase 3,Phase 2,Phase 1
40 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
41 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
42 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
43 Mitogens Phase 3,Phase 2,Phase 1
44 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
45 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
46 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
47 topoisomerase I inhibitors Phase 2, Phase 3,Phase 3,Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 3,Early Phase 1,Not Applicable
49 Hormone Antagonists Phase 2, Phase 3,Phase 3,Early Phase 1,Not Applicable
50 Antifungal Agents Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 178)
# Name Status NCT ID Phase Drugs
1 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
2 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
3 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
5 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
7 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
8 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
9 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
10 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
11 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
12 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
13 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
14 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
15 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
16 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
17 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
18 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
19 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
20 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
21 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
22 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
23 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
24 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
25 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
26 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
27 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
28 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
29 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
30 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
31 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
32 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
33 Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Unknown status NCT00003560 Phase 2 carboplatin;docetaxel
34 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
35 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
36 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
37 Phase II ABT-888 With Cyclophosphamide Completed NCT01306032 Phase 2 ABT-888;Cyclophosphamide
38 Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer Completed NCT00022620 Phase 2 paclitaxel
39 Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer Completed NCT01583322 Phase 2 vargatef;placebo
40 Uterine Papillary Serous Cancer (UPSC) Trial Completed NCT00147680 Phase 2 Paclitaxel, Carboplatin
41 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
42 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
43 Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer Completed NCT00052312 Phase 2 cisplatin;doxorubicin hydrochloride;paclitaxel
44 AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00275028 Phase 2 cediranib maleate
45 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
46 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
47 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
48 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
49 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
50 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus

Search NIH Clinical Center for Serous Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma, serous

Genetic Tests for Serous Cystadenocarcinoma

Anatomical Context for Serous Cystadenocarcinoma

MalaCards organs/tissues related to Serous Cystadenocarcinoma:

41
Ovary, Pancreas, T Cells, Bone, Liver, Lung, Bone Marrow

Publications for Serous Cystadenocarcinoma

Articles related to Serous Cystadenocarcinoma:

(show top 50) (show all 111)
# Title Authors Year
1
Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma. ( 29456732 )
2018
2
A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma. ( 30097905 )
2018
3
Gastric metastasis of ovarian serous cystadenocarcinoma. ( 30233254 )
2018
4
Bilateral Breast and Axillary Lymph Nodes Metastases of an Ovarian Serous Cystadenocarcinoma. ( 30287996 )
2018
5
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma. ( 30446011 )
2018
6
Serous cystadenocarcinoma of the spleen. ( 28491168 )
2017
7
High Grade Serous Cystadenocarcinoma of Testis-Case Report of a Rare Ovarian Epithelial Type Tumour. ( 28764180 )
2017
8
Expression of Yes-associated proteinA 1 and its clinical significance in ovarian serous cystadenocarcinoma. ( 28339095 )
2017
9
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. ( 27746113 )
2016
10
Serous Cystadenocarcinoma Arising in Presumed Vitelline Duct Remnant: A Case Report and Implications in the Management of Cancer of Unknown Primary. ( 27999702 )
2016
11
Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma. ( 27189279 )
2016
12
A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma. ( 27478834 )
2016
13
Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy. ( 27073511 )
2016
14
Serous Cystadenocarcinoma of the Pancreas: Clinical Features and Management of a Rare Tumor. ( 26998825 )
2016
15
Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases after aggressive surgical resection. ( 26177796 )
2015
16
Synchronous resection of pancreatic serous cystadenocarcinoma and liver metastasis: First reported case and review of literature. ( 26463518 )
2015
17
Solid variant type of serous cystadenocarcinoma of the pancreas: AA case report and review of the literature. ( 25716800 )
2015
18
Primary Peritoneal Papillary Serous Cystadenocarcinoma - A Rare Malignancy. ( 26713835 )
2015
19
"Sea anemone-like ciliated tumor cells" in a case of serous cystadenocarcinoma of the ovary. ( 26811576 )
2015
20
Serous Neoplasms of the Pancreas: A Clinicopathologic Analysis of 193 Cases and Literature Review With New Insights on Macrocystic and Solid Variants and Critical Reappraisal of So-called "Serous Cystadenocarcinoma". ( 26559376 )
2015
21
Serous cystadenocarcinoma of the mesentery in a man: case report and review of literature. ( 24759353 )
2014
22
Neoplasms in the trocar site and peritoneal papillary serous cystadenocarcinoma. ( 25017255 )
2014
23
Paratesticular papillary serous cystadenocarcinoma: A rare entity in Indian population. ( 25308020 )
2014
24
Ovarian serous cystadenocarcinoma metastasising to the breast. ( 23445161 )
2013
25
Histological percutaneous diagnosis of stage IV microcystic serous cystadenocarcinoma of the pancreas. ( 23370947 )
2013
26
IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma. ( 24595078 )
2013
27
Serous cystadenocarcinoma of pancreas. ( 23763806 )
2013
28
Serous cystadenocarcinoma of the pancreas: report of a case and management reflections. ( 22400805 )
2012
29
Peritoneal papillary serous cystadenocarcinoma at a previous laparoscopic trocar site. ( 23040941 )
2012
30
Imaging of pancreatic serous cystadenocarcinoma. ( 22009426 )
2011
31
Testicular papillary serous cystadenocarcinoma: a rare case report and review of the literature. ( 22355499 )
2011
32
Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen. ( 22066125 )
2011
33
Serous cystadenocarcinoma of the pancreas with portal thrombosis. ( 20499029 )
2010
34
Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. ( 21266826 )
2010
35
Collision tumor: serous cystadenocarcinoma and dermoid cyst in the same ovary. ( 18818939 )
2009
36
Pancreatic serous cystadenocarcinoma: a case report and review of the literature. ( 19459016 )
2009
37
Papillary serous cystadenocarcinoma of the stomach, peritoneum and ovary. ( 20163045 )
2009
38
Serous cystadenocarcinoma of the ovary in an 11-year-old girl with extensive dissemination and chylothorax: a case report and a brief review of literature. ( 19564753 )
2009
39
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. ( 18574502 )
2008
40
Serous cystadenocarcinoma of the pancreas with metachronous hepatic metastasis. ( 19060596 )
2008
41
Macrocystic serous cystadenocarcinoma of the pancreas: the first report of a new pattern of pancreatic carcinoma. ( 18305183 )
2008
42
Plasma cell leukemia with ovarian serous cystadenocarcinoma. ( 17883177 )
2007
43
[Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. ( 17553343 )
2007
44
Immunohistochemical identification of primary peritoneal serous cystadenocarcinoma mimicking advanced colorectal carcinoma: a case report. ( 18036260 )
2007
45
[Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. ( 16793610 )
2006
46
Paratesticular papillary serous cystadenocarcinoma--a case report. ( 16625973 )
2006
47
[ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. ( 17160949 )
2006
48
Serous cystadenocarcinoma of the pancreas: management of a rare entity. ( 16025006 )
2005
49
Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary. ( 16012716 )
2005
50
Serous cystadenocarcinoma of the pancreas. ( 15982220 )
2005

Variations for Serous Cystadenocarcinoma

Expression for Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Serous Cystadenocarcinoma.

Pathways for Serous Cystadenocarcinoma

Pathways related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 AKT1 ERBB2 FBXW7 HRAS MMP2 MUC16
2
Show member pathways
13.74 AKT1 ERBB2 ESR2 HRAS MMP2 PPP2R1A
3
Show member pathways
13.51 AKT1 ERBB2 HRAS MMP2 PIK3CA PPP2R1A
4
Show member pathways
13.48 AKT1 ERBB2 FBXW7 HRAS PIK3CA PPP2R1A
5
Show member pathways
13.38 AKT1 ERBB2 HRAS MMP2 PIK3CA PPP2R1A
6
Show member pathways
13.29 AKT1 ERBB2 ESR2 HRAS PPP2R1A VEGFA
7
Show member pathways
13.01 AKT1 ERBB2 HRAS PIK3CA PPP2R1A TP53
8
Show member pathways
12.95 AKT1 ESR2 HRAS MMP2 PGR PIK3CA
9
Show member pathways
12.92 AKT1 ERBB2 HRAS PIK3CA VEGFA
10
Show member pathways
12.92 AKT1 ERBB2 HRAS PIK3CA VEGFA
11
Show member pathways
12.91 AKT1 ERBB2 HRAS PIK3CA TP53 VEGFA
12 12.79 AKT1 ERBB2 HRAS TP53 VEGFA
13
Show member pathways
12.76 AKT1 ERBB2 HRAS PIK3CA PPP2R1A TP53
14
Show member pathways
12.75 AKT1 ERBB2 HRAS PIK3CA TP53
15
Show member pathways
12.71 AKT1 ERBB2 ESR2 HRAS PGR PIK3CA
16
Show member pathways
12.69 AKT1 HRAS MMP14 MMP2 PIK3CA VEGFA
17
Show member pathways
12.6 AKT1 ERBB2 HRAS MMP2 PIK3CA TP53
18
Show member pathways
12.58 AKT1 HRAS PIK3CA PPP2R1A
19 12.58 AKT1 ERBB2 ESR2 HRAS MMP2 PIK3CA
20 12.57 ERBB2 HRAS PIK3CA TP53 VEGFA
21
Show member pathways
12.55 AKT1 ERBB2 HRAS PIK3CA TP53
22
Show member pathways
12.55 AKT1 ERBB2 HRAS MMP2 PIK3CA TP53
23
Show member pathways
12.53 AKT1 ERBB2 ESR2 HRAS PIK3CA
24
Show member pathways
12.48 AKT1 HRAS PIK3CA PPP2R1A TP53
25
Show member pathways
12.48 AKT1 ERBB2 HRAS PIK3CA TP53
26
Show member pathways
12.47 AKT1 ERBB2 HRAS PIK3CA TP53 VEGFA
27 12.45 AKT1 HRAS PIK3CA TP53
28
Show member pathways
12.43 AKT1 HRAS PIK3CA VEGFA
29
Show member pathways
12.43 AKT1 HRAS PIK3CA VEGFA
30
Show member pathways
12.43 AKT1 HRAS PIK3CA TP53
31
Show member pathways
12.43 AKT1 ERBB2 ESR2 HRAS MMP2 PIK3CA
32
Show member pathways
12.39 AKT1 PGR PIK3CA PPP2R1A
33
Show member pathways
12.36 AKT1 ERBB2 ESR2 HRAS PIK3CA
34
Show member pathways
12.35 AKT1 ERBB2 HRAS PIK3CA
35
Show member pathways
12.34 AKT1 HRAS PIK3CA TP53
36
Show member pathways
12.29 AKT1 HRAS TP53 VEGFA
37
Show member pathways
12.25 AKT1 ERBB2 HRAS PIK3CA TP53
38 12.22 AKT1 HRAS PIK3CA TP53
39
Show member pathways
12.22 AKT1 HRAS PIK3CA TP53
40 12.21 AKT1 MMP14 MMP2 TP53 VEGFA
41
Show member pathways
12.19 AKT1 ERBB2 HRAS PIK3CA
42
Show member pathways
12.19 AKT1 HRAS PIK3CA TP53
43 12.16 AKT1 ERBB2 HRAS PIK3CA TP53
44
Show member pathways
12.14 AKT1 ERBB2 HRAS MMP2 PIK3CA
45 12.11 AKT1 MMP2 PIK3CA TP53 VEGFA
46
Show member pathways
12.09 AKT1 ERBB2 PIK3CA TP53
47 12.07 AKT1 HRAS PIK3CA PPP2R1A TP53
48 12.05 AKT1 HRAS PIK3CA TP53
49 12.04 AKT1 MMP2 TP53 VEGFA
50
Show member pathways
12.01 ERBB2 HRAS PGR PIK3CA

GO Terms for Serous Cystadenocarcinoma

Cellular components related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.97 AKT1 ERBB2 FBXW7 HRAS MMP14 MMP2
2 nucleus GO:0005634 9.77 AKT1 ERBB2 ESR2 FBXW7 HRAS MMP14
3 mitochondrion GO:0005739 9.23 AKT1 ESR2 FBXW7 MMP2 PGR PPP2R1A

Biological processes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.78 MMP14 MMP2 PIK3CA VEGFA
2 positive regulation of gene expression GO:0010628 9.77 AKT1 ERBB2 HRAS TP53 VEGFA
3 lung development GO:0030324 9.71 FBXW7 MMP14 VEGFA
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.69 AKT1 PIK3CA VEGFA
5 positive regulation of cell growth GO:0030307 9.67 AKT1 ERBB2 MMP14
6 positive regulation of epithelial cell proliferation GO:0050679 9.63 ERBB2 HRAS VEGFA
7 positive regulation of protein phosphorylation GO:0001934 9.62 AKT1 ERBB2 HRAS VEGFA
8 positive regulation of MAP kinase activity GO:0043406 9.61 ERBB2 HRAS VEGFA
9 negative regulation of macroautophagy GO:0016242 9.55 AKT1 PIK3CA
10 anoikis GO:0043276 9.52 AKT1 PIK3CA
11 negative regulation of Notch signaling pathway GO:0045746 9.43 AKT1 FBXW7 MMP14
12 circadian behavior GO:0048512 9.4 TP53 USP2
13 cytokine-mediated signaling pathway GO:0019221 9.35 AKT1 MMP2 PIK3CA TP53 VEGFA
14 phosphatidylinositol 3-kinase signaling GO:0014065 9.33 AKT1 ERBB2 PIK3CA
15 negative regulation of gene expression GO:0010629 9.02 AKT1 FBXW7 HRAS PGR VEGFA

Molecular functions related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.63 ALPP ESR2 MMP14 MMP2 PGR TP53
2 identical protein binding GO:0042802 9.56 AKT1 ERBB2 ESR2 FBXW7 PGR TP53
3 protein binding GO:0005515 9.55 AKT1 ALPP ERBB2 ESR2 FBXW7 HRAS

Sources for Serous Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....